Shire controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile2 entries
2017
Dermagraft promotion settlement
Shire reached a settlement with the U.S. Department of Justice concerning alleged violations of the False Claims Act linked to the promotion of Dermagraft.
2014
False Claims Act marketing settlement
Shire agreed to a U.S. settlement over allegations that it had improperly marketed and promoted Adderall XR, Daytrana, Vyvanse, Pentasa and Lialda during various periods. The allegations included unsupported safety and benefit claims and promotion for uses not approved by the U.S. regulator.